搜索结果: 1-5 共查到“prostatic cancer”相关记录5条 . 查询时间(0.069 秒)
Molecular genetic,diagnosis,prevention and gene therapy in prostatic cancer: review article
Molecular genetic diagnosis prevention gene therapy prostate cancer
2009/12/15
The prostate is a small gland located below the bladder and upper part of the urethra. In developed countries prostate cancer is the second common cancer (after skin cancer), and also the second leadi...
Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. II. Endocrinology and histology of the testis
Pituitary-testicular function prostatic cancer patients gonadotropin-releasing hormone
2009/2/23
Endogenous testosterone (T), LH and FSH receptors, and in vitro production of cyclic adenosine-3':5'-monophosphate (cAMP), T and some of its steroid precursors were measured in testicular tissue obt...
Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels
Pituitary-testicular function prostatic cancer patients treatment gonadotropin-releasing hormone
2009/2/23
Eight patients with advanced prostatic carcinoma (ages 59 to 78 years) were treated with a potent gonadotropin-releasing hormone (GnRH) agonist analog (buserelin, Hoechst; 600 micrograms intranasall...
Overview of enzyme inhibitors and anti-androgens in prostatic cancer
enzyme inhibitors anti-androgens prostatic cancer
2009/2/7
Surgical castration and estrogen therapy for prostate cancer were developed in 1941, and have been shown to improve both quality of life and survival. Little change in the therapeutics of prostate...
Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer
LH FSH testosterone bioactive LH buserelin
2009/2/7
Luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone (T) responses to 6-month treatments with a gonadotropin-releasing hormone (GnRH) agonist (buserelin) and subsequent orc...